No Data
Zhejiang Huahai Pharmaceutical (600521.SH): Plans to use the raised funds to increase capital for its subsidiary to implement fundraising projects.
On March 20, GELONGHUI reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that Huahai Pharmaceutical Technology, a wholly-owned subsidiary of the company, is the implementing entity for the "Digital Intelligent Manufacturing Construction Project for Formulations." To effectively promote the implementation of the fundraising plan, the company intends to increase the capital of Huahai Pharmaceutical Technology in batches with a total of 200 million yuan from raised funds and some of its own funds. Once the capital increase is completed, the registered capital of Huahai Pharmaceutical Technology will increase from 600 million yuan to 800 million yuan (subject to final approval by industrial and commercial registration), and Huahai Pharmaceutical Technology will still be a wholly-owned subsidiary of the company. This fundraising will be used for the "formulations.
Zhejiang Huahai Pharmaceutical Obtains US FDA Tentative Approval for Diabetes Drug
Zhejiang Huahai Pharmaceutical (600521.SH): The formulation product Xiglistat Metformin tablets has received temporary approval from the FDA in the USA.
On March 17, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that it received a notice from the USA Food and Drug Administration (referred to as "USA FDA") stating that the abbreviated new drug application (ANDA, which is the application for a generic drug in the USA) for sitagliptin and metformin tablets has received temporary approval (temporary approval: refers to a type of approval granted by the FDA after completing all review requirements for generic drugs, but due to unexpired patent rights or exclusive rights); sitagliptin and metformin tablets are primarily used for the treatment of type 2 diabetes. This temporary approval for sitagliptin and metformin tablets has been granted by the USA FDA.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Huahai Pharma Gets Registration Certificates for Three Drugs
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) Most Popular Amongst Retail Investors Who Own 42%, Insiders Hold 42%
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
